Key result
Post-HPV vaccine era linked to ~15% lower cervical cancer mortality, but rural-urban disparities widen.
Why the study?
Despite declines in cervical cancer mortality following HPV vaccination introduction, rural-urban, geographic, and racial disparities may persist, making understanding these trends essential for equitable prevention.
How did cervical cancer mortality and rural-urban disparities change in the US before and after HPV vaccine introduction?
Observational (n=102,205)
How did cervical cancer mortality and rural-urban disparities change in the US before and after HPV vaccine introduction?
Effect estimate: AAPC -0.86% (95% CI -1.0 to -0.7)
Absolute Event Rate: 1.09% vs 1.28%
While overall US cervical cancer mortality declined following HPV vaccine introduction, rural-urban disparities in mortality have widened.
Declining post-vaccine cervical cancer mortality with widening rural-urban gaps; observational trends leave open equitable impact and need targeted studies.
5535 Background: Cervical cancer mortality has declined in the United States following the introduction of HPV vaccination. However, disparities by urbanization, geography, and race may persist. Rural women remain up to 40% more likely to die from cervical cancer. Understanding rural–urban trends is essential to guiding equitable prevention strategies. Methods: CDC WONDER mortality data for females ≥15years with cervical cancer (ICD-10 C53) were analyzed. Age-adjusted mortality rates (AAMR) per 100,000 population were analyzed. Urbanization data were available till 2020 and were used for urban–rural stratification (NCHS classification). Temporal trends were assessed using joint point regression to determine average annual percent change (AAPC). Results: Between 1999 and 2023, 102,205 cervical cancer deaths were identified. The overall AAMR declined from 1.52 to 1.28 during the pre-vaccine era (1999–2005; AAPC = –2.95%, 95% CI –4.0 to –1.8) and further to 1.09 during the post-vaccine era (2006–2023; AAPC = –0.86%, 95% CI –1.0 to –0.7). Rural-urban mortality (AAMR) ratio increased in post-vaccine era from 1.13 vs 1.15 with 1.47% increase in disparity. By urbanization, declines were greatest in central metropolitan areas (AAMR 1.72 to 1.48 pre-vaccine; 1.14 post-vaccine; AAPC = –1.40%, 95% CI –1.6 to –1.2), while small metro (1.36 to 1.29 pre-vaccine; 1.11 post-vaccine; AAPC = –0.93%, 95% CI –1.2 to –0.6) and micropolitan areas (1.70 to 1.44 pre-vaccine; 1.32 post-vaccine; AAPC = –0.34%, 95% CI –1.3 to 0.6) showed slower improvement which widened mortality gap. Subgroup analyses showed the steepest mortality declines among women aged ≥75 years (AAPC = –3.66%), among Black women (AAPC = –2.81%), and in the Northeast region (AAPC = –2.16%). Conclusions: U.S. cervical cancer mortality declined after the HPV vaccine introduction; however, rural–urban, racial, and regional disparities persisted. Declines were slower in small metropolitan and nonmetropolitan areas and highest among Black individuals, underscoring the need for targeted vaccination, screening efforts and access-to-care.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) conducted an observational in Cervical cancer (n=102,205). HPV vaccine introduction (post-vaccine era) vs. Pre-vaccine era was evaluated on Age-adjusted mortality rates (AAMR) per 100,000 population (AAPC -0.86%, 95% CI -1.0 to -0.7). U.S. cervical cancer mortality declined in the post-HPV vaccine era to an AAMR of 1.09 (AAPC -0.86%), but the rural-urban mortality ratio increased, highlighting persistent disparities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: